CRYOFOCUS-B(06922): Malignant stenosis cryoablation system obtained approval from the National Medical Products Administration.

The CRYOFOCUS-B (06922) announced on March 6, 2025, that the group's malignant narrow cold ablation system, one of the group's respiratory intervention products, consisting of cold treatment equipment and airway cold ablation catheters, has obtained approval from the National Medical Products Administration. The malignant narrow cold ablation system is a self-developed cold ablation system used to ablate malignant airway tumor tissue and reduce the frequency of airway stenosis. During the surgery, the system utilizes the ultra-low temperature generated by the cold ablation system to ablate the tumor cells inside the tracheal lumen and wall, and then further destroys the tumor cells through rewarming. The cold ablation balloon can achieve more thorough ablation of malignant tumors over a larger area and delay the onset of stenosis.